文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

经导管主动脉瓣置换术后左心室质量消退:PARTNER试验与注册研究

Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

本研究基于PARTNER I、II和S3试验及注册研究中1年存活且基线存在中重度左心室肥厚的TAVR患者,分析1年时左心室质量指数消退与1至5年临床结局的关联。结果显示,1年时LVMi消退幅度越大,全因死亡及再住院率越低;1年时仍存在重度左心室肥厚与全因死亡风险增加独立相关。

要点

  • TAVR术后1年LVMi消退越多,1至5年全因死亡风险越低(每降低10%的aHR为0.95)。
  • 1年时仍存在重度左心室肥厚者全因死亡风险显著增高(aHR 1.71)。
  • TAVR术后左心室质量消退情况可能影响瓣膜置换时机及辅助药物治疗策略。

核心结论

  • 在TAVR术后1年存活且基线存在中重度左心室肥厚的患者中,1年时LVMi消退幅度越大与1至5年死亡和住院率越低相关。

研究设计与样本

  • 基于PARTNER I、II和S3试验及注册研究的回顾性分析,纳入中高危TAVR术后1年存活、基线存在中重度左心室肥厚且基线与1年有配对LVMi测量的患者1434例。

主要发现

  • 基线LVMi为146 g/m2(IQR 133-168 g/m2),1年时下降14.5%(IQR 4.2%-26.1%)至126 g/m2(IQR 106-148 g/m2)。
  • 校正后,1年时LVMi消退幅度越大与全因死亡风险越低相关(每降低10%的aHR为0.95;95%CI 0.91-0.98;p=0.004;消退最多四分位组 vs 最少组的aHR为0.61;95%CI 0.43-0.86;p=0.005)。
  • 1年时39%的患者存在重度左心室肥厚,其与全因死亡风险增加独立相关(重度LVH vs 无LVH的aHR为1.71;95%CI 1.20-2.44;p=0.003)。
  • 心血管死亡和再住院率也呈现类似关联。

临床怎么用

  • TAVR术后应关注左心室质量指数的消退情况,1年时仍存在重度左心室肥厚可能提示预后不良。
  • 左心室质量消退情况可能为瓣膜置换时机及TAVR术后辅助药物治疗提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Greater early left ventricular mass index (LVMi) regression is associated with fewer hospitalizations 1 year after transcatheter aortic valve replacement (TAVR). The association between LVMi regression and longer-term post-TAVR outcomes is unclear. OBJECTIVES: The purpose of this study was to determine the association between LVMi regression at 1-year post-TAVR and clinical outcomes between 1 and 5 years. METHODS: Among intermediate- and high-risk patients who received TAVR in the PARTNER (Placement of Aortic Transcatheter Valves) I, II, and S3 trials or registries and were alive at 1 year, we included patients with baseline moderate or severe left ventricular hypertrophy (LVH) and paired measurements of LVMi at baseline and 1 year. The associations between LVMi regression (percent change between baseline and 1 year) and death or rehospitalization from 1 to 5 years were examined. RESULTS: Among 1,434 patients, LVMi was 146 g/m2 (interquartile range [IQR]: 133 to 168 g/m2) at baseline and decreased 14.5% (IQR: 4.2% to 26.1%) to 126 g/m2 (IQR: 106 to 148 g/m2) at 1 year. After adjustment, greater LVMi regression at 1 year was associated with lower all-cause death (adjusted hazard ratio [aHR]: 0.95 per 10% decrease in LVMi; 95% confidence interval [CI]: 0.91 to 0.98; p = 0.004; aHR of the quartile with greatest vs. least LVMi regression: 0.61; 95% CI: 0.43 to 0.86; p = 0.005). Severe LVH at 1 year was observed in 39%, which was independently associated with increased all-cause death (aHR of severe LVH vs. no LVH: 1.71; 95% CI: 1.20 to 2.44; p = 0.003). Similar associations were found for rates of cardiovascular mortality and rehospitalization. CONCLUSIONS: Among patients with moderate or severe LVH treated with TAVR who are alive at 1 year, greater LVMi regression at 1 year is associated with lower death and hospitalization rates to 5 years. These findings may have implications for the timing of valve replacement and the role of adjunctive medical therapy after TAVR.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Chau KH, Douglas PS, Pibarot P, et al. Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries. J Am Coll Cardiol. 2020. PMID: 32408979. doi:10.1016/j.jacc.2020.03.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。